Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.

[1]  V. Devita,et al.  Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. , 1979, Annals of internal medicine.

[2]  E. Schneeberger,et al.  Chronic renal failure in children treated with methyl CCNU. , 1979, The New England journal of medicine.

[3]  N. Cascinelli,et al.  Stage I Melanoma of the Limbs: Assessment of Prognosis by Levels of Invasion and Maximum Thickness , 1978, Tumori.

[4]  Fisher Ri,et al.  Natural history of malignant melanoma as related to therapy. , 1976 .

[5]  M. Silverstein,et al.  BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience , 1974, Annals of surgery.

[6]  V. Devita,et al.  Treatment of malignant melanoma with methyl CCNU , 1974, Clinical pharmacology and therapeutics.

[7]  E. Hersh,et al.  Active immunotherapy with B.C.G. for recurrent malignant melanoma. , 1973, Lancet.

[8]  P. Ray,et al.  Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice. , 1971, Journal of the National Cancer Institute.

[9]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[10]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[11]  P. Ms,et al.  PROTECTION AGAINST RUBELLA , 1965 .

[12]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .